figshare
Browse
Table_1_Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary .docx (14.58 kB)

Table_1_Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis.docx

Download (14.58 kB)
dataset
posted on 2022-06-01, 13:09 authored by Alexandra Serris, Amani Ouedrani, Fabrice Uhel, Marianne Gazzano, Vincent Bedarida, Claire Rouzaud, Marie-Elisabeth Bougnoux, Jean-Herlé Raphalen, Sylvain Poirée, Olivier Lambotte, Guillaume Martin-Blondel, Fanny Lanternier

Invasive fungal diseases (IFD) still cause substantial morbidity and mortality, and new therapeutic approaches are urgently needed. Recent data suggest a benefit of checkpoint inhibitors (ICI). We report the case of a diabetic patient with refractory IFD following a SARSCoV-2 infection treated by ICI and interferon-gamma associated with antifungal treatment.

History